2nd Apr 2007 10:26
Hikma Pharmaceuticals Plc02 April 2007 Hikma Pharmaceuticals PLC - Voting Rights and Capital LONDON, 2 April 2007: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) notifiesthe market that as at 31 March 2007 its capital consists of 169,137,407 ordinaryshares with voting rights. There are no shares held in treasury. The above figure (169,137,407) may be used by shareholders as the denominatorfor the calculations by which they will determine if they are required to notifytheir interest in, or a change to their interest in, Hikma Pharmaceuticals PLCunder the FSA's Disclosure and Transparency Rules. - ENDS -Enquiries: Hikma Pharmaceuticals PLC Susan Ringdal +44 20 7399 2760Investor Relations Director Brunswick Group Jon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About HikmaHikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2006, the Grouphad revenue of $317 million and profit attributable to shareholders of $54.5million. For news and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals